おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Santarus
company
About
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that
- 501 - 1000
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $33.20M
- Industries
- Biopharma,Biotechnology,Health Care
- Founded date
- Jan 1, 1996
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$84.60M
Santarus has raised a total of
$84.60M
in funding over 2 rounds. Their latest funding was raised on
May 22, 2003 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 22, 2003 | Series D | $51.40M | 1 | — | — | Detail |
| Mar 8, 2001 | Series C | $33.20M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Santarus is funded by 2 investors.
New England Partners
and JP Morgan Chase
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
New England Partners
|
— | Series D |
JP Morgan Chase
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
